Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials

BACKGROUND: Zoledronic acid (ZOL) is an important component of therapy for patients with metastatic bone disease (MBD) to reduce the risk of skeletal-related events (SREs). We evaluated overall survival (OS) in patients with MBD secondary to solid tumours included in placebocontrolled ZOL trials. PA...

Descripción completa

Detalles Bibliográficos
Autores principales: Coleman, Robert E., Lipton, Allan, Costa, Luis, Cook, Richard J., Lee, Ker-Ai, Saad, Fred, Brown, Janet E., Terpos, Evangelos, Major, Pierre P., Kohno, Norio, Smith, Matthew, Body, Jean-Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723367/
https://www.ncbi.nlm.nih.gov/pubmed/26909273
http://dx.doi.org/10.1016/j.jbo.2013.01.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723367/
https://www.ncbi.nlm.nih.gov/pubmed/26909273
http://dx.doi.org/10.1016/j.jbo.2013.01.002

Ejemplares similares